Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H40N4O10 |
Molecular Weight | 496.5524 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 15 / 15 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]3(O[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O[C@@]2([H])OC[C@](C)(O)[C@H](NC)[C@H]2O)[C@H]1O)O[C@]([H])([C@@H](C)O)[C@@H](O)[C@H](O)[C@H]3N
InChI
InChIKey=BRZYSWJRSDMWLG-DJWUNRQOSA-N
InChI=1S/C20H40N4O10/c1-6(25)14-11(27)10(26)9(23)18(32-14)33-15-7(21)4-8(22)16(12(15)28)34-19-13(29)17(24-3)20(2,30)5-31-19/h6-19,24-30H,4-5,21-23H2,1-3H3/t6-,7+,8-,9-,10-,11+,12+,13-,14-,15-,16+,17-,18-,19-,20+/m1/s1
Molecular Formula | C20H40N4O10 |
Molecular Weight | 496.5524 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 15 / 15 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/6159822Curator's Comment: description was created based on several sources, including:
http://www.invivogen.com/g418 | http://www.g418-evopure.com/Technical.html
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6159822
Curator's Comment: description was created based on several sources, including:
http://www.invivogen.com/g418 | http://www.g418-evopure.com/Technical.html
Geneticin (G-418) is produced by Micromonospora phodorangea. The antibiotic has brad spectrum antibacterial activity similar to gentamicins and other previously described aminoglycosides but of particular interest because of its high activity against protozoa, amoebae, tapeworm and pinworm infections in mice. G418 blocks polypeptide synthesis by inhibiting the elongation step in both prokaryotic and eukaryotic cells. G418 is commonly used in laboratory research to select genetically engineered cells.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Paromomycin and geneticin inhibit intracellular Cryptosporidium parvum without trafficking through the host cell cytoplasm: implications for drug delivery. | 1998 Aug |
|
Inhibition of HIV type 1 production by hygromycin B. | 1998 Jul 1 |
|
Aminoglycoside pretreatment partially restores the function of truncated V(2) vasopressin receptors found in patients with nephrogenic diabetes insipidus. | 2002 Nov |
|
Classification and rescue of ROMK mutations underlying hyperprostaglandin E syndrome/antenatal Bartter syndrome. | 2003 Sep |
|
Cytochrome c release and endoplasmic reticulum stress are involved in caspase-dependent apoptosis induced by G418. | 2004 Jul |
|
Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo. | 2004 May 1 |
|
Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. | 2004 Nov 2 |
|
Aminoglycosides decrease glutathione peroxidase-1 activity by interfering with selenocysteine incorporation. | 2006 Feb 10 |
|
Intracellular readthrough of nonsense mutations by aminoglycosides in coagulation factor VII. | 2006 Jun |
|
Restoration of W1282X CFTR activity by enhanced expression. | 2007 Sep |
|
G418-mediated ribosomal read-through of a nonsense mutation causing autosomal recessive proximal renal tubular acidosis. | 2008 Sep |
|
Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo. | 2009 Apr 1 |
|
Stop codon read-through of a methylmalonic aciduria mutation. | 2009 Aug |
|
ATP-binding cassette transporters as pitfalls in selection of transgenic cells. | 2010 Apr 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19150990
4 mg/kg to neonatal mice from postnatal day (PND) 5–13.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6378088
All of the Saccharomyces sp. strains, including the brewing strains, were found to be susceptible to G418 in the concentration range of 150 to 500 ug/ml. Of the three Schwanniomyces species investigated, only Schwanniomyces castellii (strain 1402) was found to be resistant to G418 at concentrations up to 1 mg/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:07:23 GMT 2023
by
admin
on
Fri Dec 15 15:07:23 GMT 2023
|
Record UNII |
A08F5XTI6G
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
204605
Created by
admin on Fri Dec 15 15:07:23 GMT 2023 , Edited by admin on Fri Dec 15 15:07:23 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
123865
Created by
admin on Fri Dec 15 15:07:23 GMT 2023 , Edited by admin on Fri Dec 15 15:07:23 GMT 2023
|
PRIMARY | |||
|
DTXSID10198129
Created by
admin on Fri Dec 15 15:07:23 GMT 2023 , Edited by admin on Fri Dec 15 15:07:23 GMT 2023
|
PRIMARY | |||
|
A08F5XTI6G
Created by
admin on Fri Dec 15 15:07:23 GMT 2023 , Edited by admin on Fri Dec 15 15:07:23 GMT 2023
|
PRIMARY | |||
|
42768
Created by
admin on Fri Dec 15 15:07:23 GMT 2023 , Edited by admin on Fri Dec 15 15:07:23 GMT 2023
|
PRIMARY | |||
|
G418
Created by
admin on Fri Dec 15 15:07:23 GMT 2023 , Edited by admin on Fri Dec 15 15:07:23 GMT 2023
|
PRIMARY | |||
|
49863-47-0
Created by
admin on Fri Dec 15 15:07:23 GMT 2023 , Edited by admin on Fri Dec 15 15:07:23 GMT 2023
|
PRIMARY | |||
|
DB04263
Created by
admin on Fri Dec 15 15:07:23 GMT 2023 , Edited by admin on Fri Dec 15 15:07:23 GMT 2023
|
PRIMARY |